Singapore Eye Research Institute
ScholarGPS Institution Ranking

Clinical Trials

Medical discoveries do not happen by chance. Through clinical trials, doctors and scientists understand how to diagnose, treat, cure or prevent diseases. Taking part in trials not only benefits those you love but it helps future generations and others with the same disease. SERI houses a dedicated research clinic facility to conduct comprehensive clinical trials and research studies.

Find out more

Technologies Available for Licensing

SERI researchers continuously produce inventions and discoveries with market potential, and we look to bring these to market either via licensing or creation of dedicated spin-offs. We are seeking industrial partners to license and commercialize several technologies which are more mature and ready for advanced testing, development and deployment.

Find out more

Research at Myopia Centre We’re on a mission. To create solutions, prevent and treat myopia to stop the rising onset of a global epidemic. Click to learn more!

Research Bulletin SERI has been involved in conducting high-impact eye research since its establishment in 1997, with the aim to prevent blindness, low vision and major eye diseases prevalent in Singaporeans and Asians. Read more about the path-breaking research and insights here.

Research PhD Programmes Research PhD programmes are available in the various institutes. Check them out here.

Give to VisionSave

Your generosity will go a long way towards providing financial assistance for needy patients, funding research for better treatments and training the next generation of eye specialists for excellent patient care. Join us in paving the way to a brighter future by making a donation today.

Donate now

Recent News

Research Formosa Pharmaceuticals and SERI Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – Formosa Pharmaceuticals, Inc. (“Formosa”, 6838.TW) and the Singapore Eye Research Institute (“SERI”) are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI’s world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD. The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice. Synergy of Innovation and Clinical Excellence A/Prof Yu-Chi Liu, clinician scientist at Singapore National Eye Center and Principal Investigator at SERI, brings extensive experience in corneal neuropathy and translational medicine to the collaboration. Her recent work in diabetic keratopathy and ocular surface inflammation will be pivotal in guiding the development of formulations targeting complex anterior segment conditions. "Collaborating with Formosa Pharmaceuticals allows us to bridge the gap between benchside innovation and bedside application," said A/Prof. Yu-Chi Liu. "Our goal is to utilize advanced formulation technologies like APNT to create treatments that are not only more effective but also less burdensome for patients suffering from ocular conditions." Leveraging APNT® Technology Formosa Pharmaceuticals’ APNT® platform specializes in reducing the particle size of active pharmaceutical ingredients (APIs) to stable, uniform nanoparticles. This technology is a hallmark of Formosa's development pipeline, offering a powerful solution for improving the delivery of poorly soluble drugs to the target tissues and organs. "We are honored to work alongside Professor Liu and her distinguished team at SERI," said Erick Co, President & CEO of Formosa Pharmaceuticals. "Initial efforts have confirmed compatibility of APNT and SERI’s research models and prompt us to extend our partnership. SERI’s reputation for excellence in vision research, backed by their comprehensive capabilities and facilities, are unparalleled. Together, we are excited to translate the research findings into better clinical outcomes."

30 Apr 2026 Read Story

Announcements Singapore Eye Research Institute tops ScholarGPS rankings in Ophthalmology The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally.

28 Jan 2026 Read Story

Announcements S’pore institute in $21m tie-up to develop treatments for eye diseases SERI and Santen has launched SONIC 2.0, a $21 million initiative to develop treatments for eye diseases like glaucoma and myopia. The three-year collaboration builds on SONIC 1.0, which resulted in 13 research projects and the development of low-dose atropine drops for myopia. SONIC 2.0 aims to develop two treatments to the clinical stage, expand the use of ophthalmic drugs and contribute to Singapore's biomedical innovation.

04 Dec 2025 | The Straits Times Read Story

View All News